Merck KGaA (MKKGY) News Today $29.15 -0.15 (-0.51%) As of 03/12/2025 03:59 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartDividendEarningsHeadlinesShort Interest All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period UBS Sticks to Their Buy Rating for Merck KGaA (0O14)March 12 at 9:36 PM | markets.businessinsider.comMerck KGaA (OTCMKTS:MKKGY) Posts Quarterly Earnings Results, Beats Expectations By $0.07 EPSMerck KGaA (OTCMKTS:MKKGY - Get Free Report) released its earnings results on Thursday. The company reported $0.54 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.47 by $0.07. Merck KGaA had a net margin of 12.89% and a return on equity of 10.41%.March 7, 2025 | marketbeat.comMerck KGaA (0O14) Receives a Buy from Goldman SachsMarch 6, 2025 | markets.businessinsider.comMerck KGaA (MKGAF) Q4 2024 Earnings Call TranscriptMarch 6, 2025 | seekingalpha.comMerck KGaA (OTCMKTS:MKKGY) Short Interest UpdateMerck KGaA (OTCMKTS:MKKGY - Get Free Report) saw a significant decline in short interest during the month of February. As of February 15th, there was short interest totalling 1,000 shares, a decline of 98.1% from the January 31st total of 53,500 shares. Based on an average daily trading volume, of 176,700 shares, the short-interest ratio is currently 0.0 days.February 28, 2025 | marketbeat.comUBS Keeps Their Buy Rating on Merck KGaA (0O14)February 28, 2025 | markets.businessinsider.comMerck KGaA (MKKGY) to Release Quarterly Earnings on ThursdayMerck KGaA (OTCMKTS:MKKGY) will be releasing earnings before the market opens on Thursday, March 6, Financial Modeling Prep reports.February 27, 2025 | marketbeat.comMerck Gets Speedy FDA Review of Keytruda in Certain Head, Neck CancersFebruary 25, 2025 | marketwatch.comMerck KGaA (OTCMKTS:MKKGY) Stock Price Down 0.7% - Should You Sell?Merck KGaA (OTCMKTS:MKKGY) Stock Price Down 0.7% - Time to Sell?February 21, 2025 | marketbeat.comMerck vaccine trial delayed as RFK Jr. link creates jury concernFebruary 19, 2025 | latimes.comNew CEOs to join Merck KGaA’s executive boardFebruary 19, 2025 | finance.yahoo.comMerck vaccine case linked to Kennedy delayed mid-trial, Reuters reportsFebruary 19, 2025 | markets.businessinsider.comMerck Foundation Marks International Day of Girls & Women in Science Through Their MARS AwardsFebruary 12, 2025 | msn.comGermany's Merck In Talks To Buy Cancer Drug Maker SpringWorks TherapeuticsFebruary 11, 2025 | benzinga.comMerck KGaA verhandelt Milliardendeal mit US-TumorspezialistenFebruary 11, 2025 | msn.comMerck KGaA confirms ‘advanced’ talks to acquire SpringWorksFebruary 11, 2025 | markets.businessinsider.comGermany’s Merck in Talks to Buy SpringWorks TherapeuticsFebruary 11, 2025 | msn.comMerck KGaA (OTCMKTS:MKKGY) Reaches New 12-Month Low - Should You Sell?Merck KGaA (OTCMKTS:MKKGY) Hits New 1-Year Low - Here's WhyFebruary 10, 2025 | marketbeat.comSpringWorks Therapeutics jumps on report of Merck KGaA takeover talksFebruary 10, 2025 | seekingalpha.comExclusive: Germany's Merck KGaA in talks to buy US cancer biotech firm Springworks, sources sayFebruary 10, 2025 | reuters.comGoldman Sachs Sticks to Their Buy Rating for Merck KGaA (0O14)February 10, 2025 | markets.businessinsider.comJ.P. Morgan Reaffirms Their Buy Rating on Merck KGaA (0O14)February 8, 2025 | markets.businessinsider.comMerck 2025 sales forecast underwhelms as it pauses Gardasil sales in ChinaFebruary 6, 2025 | msn.comBernstein Sticks to Its Hold Rating for Merck & Company (MRK)February 6, 2025 | markets.businessinsider.comMerck Stock Down 8% On Weak Outlook, Q4 Results Miss EstimatesFebruary 4, 2025 | markets.businessinsider.comMerck falls -10.8%February 4, 2025 | markets.businessinsider.comMerck Shares Hit After Guidance Falls Short, Gardasil ChallengeFebruary 4, 2025 | wsj.comMerck’s Winrevair: A Catalyst for Stock Growth Amid Promising Clinical DevelopmentsFebruary 3, 2025 | markets.businessinsider.comMerck KGaA (MKGAF) Faces 11% Stock Decline Despite AI-Driven Growth Outlook and Analyst Price Target of €200January 31, 2025 | insidermonkey.comMerck Stops Winrevair Study Early Amid Positive ResultsJanuary 31, 2025 | marketwatch.comDeutsche Bank Sticks to Their Buy Rating for Merck KGaA (0O14)January 31, 2025 | markets.businessinsider.comMerck to stop Phase 3 HYPERION trialJanuary 30, 2025 | markets.businessinsider.comMerck To Stop Phase 3 HYPERION Study EarlyJanuary 30, 2025 | markets.businessinsider.comMerck KGaA (OTCMKTS:MKKGY) Short Interest Up 4,075.0% in JanuaryMerck KGaA (OTCMKTS:MKKGY - Get Free Report) was the recipient of a significant growth in short interest during the month of January. As of January 15th, there was short interest totalling 16,700 shares, a growth of 4,075.0% from the December 31st total of 400 shares. Based on an average daily volume of 329,400 shares, the days-to-cover ratio is currently 0.1 days.January 29, 2025 | marketbeat.comMerck price target lowered to $125 from $130 at CitiJanuary 28, 2025 | markets.businessinsider.comMerck: FDA grants priority review to sNDA for WeliregJanuary 27, 2025 | markets.businessinsider.comMerck Gets FDA Priority Review of Welireg in Rare Adrenal TumorsJanuary 27, 2025 | marketwatch.comMerck, Eisai provide update on Phase 3 LEAP-015 trialJanuary 24, 2025 | markets.businessinsider.comMerck, Eisai See Mixed Keytruda/Lenvima Results in Phase 3 Gastroesophageal Cancer StudyJanuary 24, 2025 | marketwatch.comMerck and Opentrons to automate assay kits on custom workstationJanuary 24, 2025 | finance.yahoo.comMerck KGaA says high asset prices call for prudent M&A approachJanuary 23, 2025 | reuters.comMilliporeSigma Partners with Opentrons Labworks, Inc., Supporting Lab of the FutureJanuary 23, 2025 | financialpost.comMerck KGaA, Darmstadt, Germany Announces Launch of Caregiver Leave Benefit, Strengthening Inclusive Family-Friendly OfferingsJanuary 22, 2025 | financialpost.comExclusive-Kennedy Played Key Role in Vaccine Case Against MerckJanuary 19, 2025 | usnews.comMerck price target lowered to $122 from $130 at GuggenheimJanuary 17, 2025 | markets.businessinsider.comMerck & Company: Strategic Shifts and Upcoming Catalysts Amidst Keytruda ChallengesJanuary 15, 2025 | markets.businessinsider.comMerck & Company: Balancing Growth Prospects with Competitive Challenges in Oncology and ImmunologyJanuary 14, 2025 | markets.businessinsider.comMerck KGaA (OTCMKTS:MKKGY) Sees Large Increase in Short InterestMerck KGaA (OTCMKTS:MKKGY - Get Free Report) saw a large increase in short interest during the month of December. As of December 31st, there was short interest totalling 16,700 shares, an increase of 4,075.0% from the December 15th total of 400 shares. Based on an average trading volume of 329,400 shares, the short-interest ratio is currently 0.1 days.January 13, 2025 | marketbeat.comMerck price target lowered to $120 from $125 at UBSJanuary 8, 2025 | markets.businessinsider.comMirror Biologics Enters Clinical Collaboration with Merck KGaA, Darmstadt, Germany in Metastatic Colorectal CancerJanuary 8, 2025 | markets.businessinsider.com Remove Ads Get Merck KGaA News Delivered to You Automatically Sign up to receive the latest news and ratings for MKKGY and its competitors with MarketBeat's FREE daily newsletter. Email Address MKKGY Media Mentions By Week MKKGY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MKKGY News Sentiment▼0.340.75▲Average Medical News Sentiment MKKGY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MKKGY Articles This Week▼63▲MKKGY Articles Average Week Remove Ads Get Merck KGaA News Delivered to You Automatically Sign up to receive the latest news and ratings for MKKGY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Regeneron Pharmaceuticals News Today Takeda Pharmaceutical News Today UCB News Today UCB News Today Alnylam Pharmaceuticals News Today Beigene News Today Bayer Aktiengesellschaft News Today Royalty Pharma News Today Merck KGaA News Today Teva Pharmaceutical Industries News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:MKKGY) was last updated on 3/13/2025 by MarketBeat.com Staff From Our PartnersElon Musk Wants to Audit Fort Knox—What It Means for Your RetirementYou can take advantage of the coming tariff-fueled gold melt-up right inside your IRA or 401(k) – 100% TAX-FRE...Colonial Metals | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredThe real reason gold is soaring (and likely to continue)Trump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Merck KGaA Please log in to your account or sign up in order to add this asset to your watchlist. Share Merck KGaA With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
